Programme in Lipidomic Oncology
Lead Research Organisation:
Babraham Institute
Department Name: UNLISTED
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Technical Summary
The control of cell function by changes in gene expression is ultimately reflected in metabolic changes. Lipids are both important metabolites and key regulators in cells. It is now clear that an individual cell can contain thousands of distinct lipid species and that the pattern of these changes in disease. In this project we aim to determine changes that are associated with the progression of cancer and thus identify disease-associated changes which may point to novel sites for therapeutic intervention.
Planned Impact
unavailable
People |
ORCID iD |
| Michael Wakelam (Principal Investigator) |
Publications
Clark J
(2011)
Quantification of PtdInsP3 molecular species in cells and tissues by mass spectrometry.
in Nature methods
Fahy E
(2009)
Update of the LIPID MAPS comprehensive classification system for lipids.
in Journal of lipid research
Huang-Doran I
(2016)
Insulin resistance uncoupled from dyslipidemia due to C-terminal PIK3R1 mutations.
in JCI insight
Kilbey A
(2010)
Runx regulation of sphingolipid metabolism and survival signaling.
in Cancer research
Kilbey A
(2017)
Runx1 Orchestrates Sphingolipid Metabolism and Glucocorticoid Resistance in Lymphomagenesis.
in Journal of cellular biochemistry
Ludwig C
(2009)
Fast targeted multidimensional NMR metabolomics of colorectal cancer.
in Magnetic resonance in chemistry : MRC
Michael Wakelam (Author)
(2009)
Lipid systems and techniques. Introduction.
in Methods in molecular biology (Clifton, N.J.)
Muinonen-Martin AJ
(2014)
Melanoma cells break down LPA to establish local gradients that drive chemotactic dispersal.
in PLoS biology
Read ML
(2016)
The proto-oncogene PBF binds p53 and is associated with prognostic features in colorectal cancer.
in Molecular carcinogenesis
Rudge SA
(2014)
SnapShot: Lipid kinase and phosphatase reaction pathways.
in Cell
| Description | This work together with others worldwide contributed to establishing lipidomics as a key methodology in the study of cell function in health and disease. This was through the development of mass spectrometry methodologies and through key nomenclature developments. |
| Exploitation Route | This has provided methods of use to other labs. |
| Sectors | Agriculture Food and Drink Pharmaceuticals and Medical Biotechnology |
| Title | Pathway analysis |
| Description | Development of pathway analysis allowing for identification of enzyme activities modulated by cell stimulation, infection or metabolic change utilising novel bioinformatics methods. |
| Type Of Material | Model of mechanisms or symptoms - mammalian in vivo |
| Year Produced | 2017 |
| Provided To Others? | Yes |
| Impact | Identification of potential therapeutic targets to treat infection. |
| Title | LIPID MAPS |
| Description | LIPID MAPS is a website which hosts tools for analysing lipidomics data and databases of MS data |
| Type Of Material | Database/Collection of data |
| Provided To Others? | Yes |
| Impact | Now the international reference for lipidomics |
| URL | http://www.lipidmaps.org/ |
| Description | AZ CRT Lipidomics consortium |
| Organisation | AstraZeneca |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Provision of lipidomic analysis of cancer cells and tissues |
| Collaborator Contribution | Consortium to investigate role of lipid metabolising enzymes in malignancy |
| Impact | Schug et al Cancer Cell 27, 57-71 |
| Start Year | 2013 |
| Description | AZ CRT Lipidomics consortium |
| Organisation | Beatson Institute for Cancer Research |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Provision of lipidomic analysis of cancer cells and tissues |
| Collaborator Contribution | Consortium to investigate role of lipid metabolising enzymes in malignancy |
| Impact | Schug et al Cancer Cell 27, 57-71 |
| Start Year | 2013 |
| Description | AZ CRT Lipidomics consortium |
| Organisation | Cancer Research UK |
| Department | Cancer Research UK London Research Institute (LRI) |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Provision of lipidomic analysis of cancer cells and tissues |
| Collaborator Contribution | Consortium to investigate role of lipid metabolising enzymes in malignancy |
| Impact | Schug et al Cancer Cell 27, 57-71 |
| Start Year | 2013 |
| Description | AZ CRT Lipidomics consortium |
| Organisation | Imperial College London |
| Department | Department of Surgery and Cancer |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Provision of lipidomic analysis of cancer cells and tissues |
| Collaborator Contribution | Consortium to investigate role of lipid metabolising enzymes in malignancy |
| Impact | Schug et al Cancer Cell 27, 57-71 |
| Start Year | 2013 |
| Description | AZ CRT Lipidomics consortium |
| Organisation | University of Oxford |
| Department | Department of Oncology |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Provision of lipidomic analysis of cancer cells and tissues |
| Collaborator Contribution | Consortium to investigate role of lipid metabolising enzymes in malignancy |
| Impact | Schug et al Cancer Cell 27, 57-71 |
| Start Year | 2013 |